January 13, 2015

CE Mark Indication Expanded for CeloNova's Embozene Microspheres

January 14, 2015—CeloNova BioSciences, Inc. announced that it has received an expanded indication to its CE Mark approval in Europe for its Embozene embolic microspheres to include the treatment of benign prostatic hyperplasia. CeloNova’s Embozene microspheres first received CE Mark approval in November 2005 and are currently available in more than 45 countries.

According to CeloNova BioSciences, prostatic artery embolization offers a minimally invasive treatment alternative for benign prostatic hyperplasia compared to the current surgical standard of care, transurethral resection of the prostate.

“The symptoms of benign prostatic hyperplasia can cause significant impact in a patient’s quality of life, and prostatic artery embolization offers a safe and effective treatment option for men,” commented Prof. Ulf Teichgraeber, MD, in the company’s press release. Prof. Teichgraeber is Director of Radiology at University Hospital in Jena, Germany.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

January 13, 2015

CE Mark Indication Expanded for CeloNova's Embozene Microspheres

Current Issue

Keep In Touch